Allogeneic hematopoietic cell transplantation (allo-HCT) is possible in older sufferers with myelodysplastic syndrome (MDS), in line with a research printed on-line June 26 within the European Journal of Haematology.
Fernando Barroso Duarte, Ph.D., from Walter Cantídio University Hospital in Fortaleza, Brazil, and colleagues carried out a retrospective multicenter study to match outcomes and assess dangers related to allo-HCT in sufferers with MDS aged 65 years and older versus youthful than 65 years throughout 38 transplant facilities in Latin America from 1988 to 2023. A complete of 441 sufferers had been enrolled; 16% had been aged 65 years and older.
The researchers discovered that general survival (OS) was 49.3% and 56.7% in sufferers 65 years and older and people youthful than 65 years, respectively, at 5 years, and progression-free survival (PFS) was 48.4% and 56.2%, respectively. The cumulative incidence charges of relapse and nonrelapse mortality had been 13.6% and 33.8%, respectively. No vital variations had been seen between the age teams in OS, nonrelapse mortality, or PFS after propensity rating matching. There was an affiliation seen between PFS in sufferers aged 65 years and older with high-risk Revised International Prognostic Scoring System stratification. The next danger for relapse was seen for sufferers aged 65 years and older in contrast with these aged youthful than 65 years. Prevalence danger was related to male intercourse, reduced-intensity conditioning, mobilized blood cells, and prior remedy in sufferers aged 65 years and older, whereas in these aged youthful than 65 years, associations had been seen with problems and persistent graft-versus-host illness.
“Allo-HCT is possible in aged sufferers with MDS, with no vital variations in OS or mortality danger in comparison with youthful sufferers,” the authors write. “However, age might affect illness development in very high-risk aged sufferers with MDS, in addition to the chance of relapse after transplantation. We recognized that male intercourse, using a reduced-intensity conditioning routine, and a mobilized blood cell graft are prevalent danger components related to aged sufferers with MDS present process HCT.”
More data:
Fernando Barroso Duarte et al, Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry, European Journal of Haematology (2025). DOI: 10.1111/ejh.70001
Citation:
Allogeneic HCT possible in older sufferers with myelodysplastic syndrome ( 23)
24
allogeneic-hct-feasible-older-patients.html
The content material is offered for data functions solely.